share_log

Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $22 Price Target

Benzinga ·  May 31, 2023 08:13

Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment